Proportion of Patients With an ACR Response1
The percentages of tofacitinib-treated patients achieving ACR20, ACR50 and ACR70 responses in studies RA-I, IV and V are shown in the table below. Similar results were observed with studies RA II and III. In trials RA I through V, patients treated with 5 mg BID tofacitinib had higher ACR20, ACR50 and ACR70 response rates versus those treated with placebo, with or without background DMARD treatment, at Month 3 and Month 6. Higher ACR20 response rates were observed within 2 weeks compared with placebo. In the 12-month trials, ACR response rates in tofacitinib-treated patients were consistent with those at 6 and 12 months.
*N is the number of randomised and treated patients.
†NA, as data for the placebo treatment is not available beyond 3 months in studies I and V due to placebo advancement.
‡IR to at least 1 DMARD (biologic or nonbiologic) due to the lack of efficacy or toxicity.
§IR to MTX defined as the presence of sufficient residual disease activity to meet the entry criteria.
||IR to at least 1 TNF blocker due to the lack of efficacy and/or intolerance.
ACR, American College of Rheumatology; BID, twice daily; IR, inadequate responder; DMARD, disease-modifying antirheumatic drug; MTX, methotrexate; NA, not applicable; PBO, placebo; RA, rheumatoid arthritis; TNF, tumour necrosis factor.
XELJANZ® (tofacitinib citrate) is a small molecule that selectively targets the JAK pathway
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022